[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100634194":3},{"organization":4,"outcomesModule":7,"designInfo":61,"detailedDescription":60,"studyPopulation":60,"armGroups":67,"interventions":76,"overallOfficials":60,"centralContacts":88,"locations":96,"responsibleParty":111,"collaborators":60,"id":115,"slug":60,"hasResults":116,"nctId":117,"briefTitle":118,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":116,"sex":121,"minAge":122,"maxAge":60,"enrollmentInfo":123,"targetDuration":60,"studyType":126,"phases":127,"briefSummary":128,"conditions":129,"keywords":60,"overallStatus":99,"whyStopped":60,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":140},{"fullName":5,"class":6},"Medical University of Vienna","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":60},[9],{"measure":10,"description":11,"timeFrame":12},"Ocular blood flow (LSFG)","Ocular Blood Flow measured by Laser Speckle Flowgraphy (LSFG) in arbitrary units","From enrollment to last study day (=5-11 weeks)",[14,17,20,23,25,28,31,34,37,40,43,45,48,51,54,57],{"measure":15,"description":16,"timeFrame":12},"Retinal vessel diameter","Retinal vessel diameter with DVA",{"measure":18,"description":19,"timeFrame":12},"Retinal oxygen saturation","Retinal oxygen saturation with DVA",{"measure":21,"description":22,"timeFrame":12},"Retinal oxygen extraction","Retinal oxygen extraction will be calculated from measurements of ocular blood flow and retinal oxygen saturation. The calculation will be based on a formula integrating these parameters to estimate retinal oxygen extraction.\n\nUnit of Measure: Arbitrary units",{"measure":24,"description":24,"timeFrame":12},"Oxygen and carbon dioxide partial pressure in arterialized blood",{"measure":26,"description":27,"timeFrame":12},"Central retinal thickness","Central retinal thickness with OCT",{"measure":29,"description":30,"timeFrame":12},"Retinal nerve fiber layer thickness","Retinal nerve fiber layer thickness with OCT",{"measure":32,"description":33,"timeFrame":12},"Retinal and choroidal microvasculature","Retinal and choroidal microvasculature with OCT-A",{"measure":35,"description":36,"timeFrame":12},"Capillary blood glucose level","Capillary blood glucose level in mg\u002FdL",{"measure":38,"description":39,"timeFrame":12},"Autonomic and sensomotoric neuropathy measurements","Short-term spectral analysis of Heart rate variability (HRV) is obtained from recordings consisting of 256 seconds of artifact free recordings. Parameters of frequency-domain HRV are measured within the low-frequency band and high-frequency band, as well as total spectral variability. Outcome variables are spectral power (ms2) in both frequency bands as well as cumulative indices.",{"measure":41,"description":42,"timeFrame":12},"Ocular perfusion pressure","Ocular perfusion pressure is calculated from systemic blood pressure and intraocular pressure.\n\nUnit of measurement: mmHg",{"measure":44,"description":44,"timeFrame":12},"Intraocular pressure",{"measure":46,"description":47,"timeFrame":12},"Systemic hemodynamics - Blood pressure","Systolic and diastolic blood pressure is measured.\n\nUnit: mmHg",{"measure":49,"description":50,"timeFrame":12},"Schirmer I Test","Schirmer I Test is performed.\n\nUnit of measuremnt: mm",{"measure":52,"description":53,"timeFrame":12},"Finger sweat sampling","Finger sweat samples will be collected using stamped-out filter paper applied to the fingertip under standardized conditions. Samples will be analyzed using an untargeted multi-omics approach.\n\nProteomic, eicosadomic, and metabolomic profiles will be assessed using high-resolution mass spectrometry platforms.\n\nUnit of Measure: Arbitrary units (normalized intensity values)",{"measure":55,"description":56,"timeFrame":12},"Systemic hemodynamics - Heart rate","Heart rate is measured.\n\nUnit: Hz",{"measure":58,"description":59,"timeFrame":12},"Systemic hemodynamics - Oxygen saturation","Oxygen saturation is measured. Unit: %",null,{"allocation":62,"interventionModel":63,"interventionModelDescription":60,"primaryPurpose":64,"observationalModel":60,"timePerspective":60,"maskingInfo":65},"NA","SINGLE_GROUP","DIAGNOSTIC",{"masking":66,"maskingDescription":60,"whoMasked":60},"NONE",[68],{"label":69,"type":70,"description":71,"interventionNames":72},"Diabetes mellitus GLP1-RA","EXPERIMENTAL","Measurements of the Ocular Blood Flow and Retinal Oxygen Extraction are performed.",[73,74,75],"Device: • Laser Speckle Flowgraphy (LSFG)","Device: • Optical Coherence Tomography (OCT)","Device: • Optical Coherence Tomography Angiography (OCT-A)",[77,82,85],{"type":78,"name":79,"description":80,"armGroupLabels":81,"otherNames":60},"DEVICE","• Laser Speckle Flowgraphy (LSFG)","Laser Speckle Flowgraphy (LSFG)",[69],{"type":78,"name":83,"description":83,"armGroupLabels":84,"otherNames":60},"• Optical Coherence Tomography (OCT)",[69],{"type":78,"name":86,"description":86,"armGroupLabels":87,"otherNames":60},"• Optical Coherence Tomography Angiography (OCT-A)",[69],[89,94],{"name":90,"role":91,"phone":92,"phoneExt":60,"email":93},"Doreen Schmidl, Prof. Priv. Doz. MD.; PhD","CONTACT","+431404002981","doreen.schmidl@meduniwien.ac.at",{"name":95,"role":91,"phone":92,"phoneExt":60,"email":60},"Doreen Schmidl, Prof. Priv. Doz. MD, PhD",[97],{"facility":98,"status":99,"city":100,"state":101,"zip":102,"country":103,"countryCode":104,"cosmosGeoPoint":105,"geoPoint":110,"contacts":60},"Medical University Vienna","RECRUITING","Vienna","State of Vienna","1090","Austria","AT",{"type":106,"coordinates":107},"Point",[108,109],16.37208,48.20849,{"lat":109,"lon":108},{"type":112,"investigatorFullName":113,"investigatorTitle":114,"investigatorAffiliation":5,"oldNameTitle":60,"oldOrganization":60},"PRINCIPAL_INVESTIGATOR","Doreen Schmidl","Assoc. Prof. Priv. Doz. Dr., PhD","100634194",false,"NCT07536516","Measurement of Ocular Blood Flow and Retinal Oxygen Extraction in Diabetic Patients","DM OPF ROXY","Inclusion Criteria:\n\n* Men and women aged ≥ 18 years\n* Signed informed consent\n* Previously diagnosed diabetes mellitus\n* Normal ophthalmic findings except diabetic retinopathy, unless the investigator considers an abnormality to be clinically irrelevant\n* Planned initiation of therapy with GLP-1 receptor agonist (Semaglutide, Ozempic®; Liraglutide, Victoza®) or GIP\u002FGLP-1 receptor agonist (Tirzepatide, Mounjaro®) by a diabetes specialist\n\nExclusion Criteria:\n\n* Participation in a clinical trial in the 3 weeks preceding the screening visit\n* Symptoms of a clinically relevant illness in the 3 weeks before the first study day\n* Presence or history of a severe medical condition, except diabetes, as judged by the clinical investigator\n* Abuse of alcoholic beverages\n* Blood donation during the previous three weeks\n* Presence of any abnormalities preventing reliable measurements in the study eye as judged by the investigator\n* Previous laser photocoagulation treatment in the study eye\n* Best corrected visual acuity \\\u003C 0.4 Snellen\n* Women of childbearing potential (neither menopausal, nor hysterectomized, nor sterilized) not using effective contraception\n* Pregnancy, planned pregnancy or lactation","ALL","18 Years",{"count":124,"type":125},20,"ESTIMATED","INTERVENTIONAL",[62],"The prevalence of diabetes is increasing, with type 2 diabetes mellitus comprising over 90% of cases. Diabetes mellitus complications, including diabetic retinopathy (DR), impose significant health burdens. GLP-1 receptor agonists (GLP-1RAs) and dual GIP\u002FGLP-1 receptor agonists show promise in improving cardiovascular and kidney outcomes, but their effects on retinal microvasculature and neuroprotection remain unclear. This study investigates the impact of GLP-1RAs (semaglutide, liraglutide) and GIP\u002FGLP-1-dual agonists (tirzepatide) on ocular blood flow and retinal function in DM patients.",[130],"Diabetes Mellitus","2026-04-10",{"date":133,"type":134},"2026-04-17","ACTUAL",{"date":136,"type":134},"2025-11-28",{"date":138,"type":125},"2026-06-01",{"name":5,"class":6},1]